Skip to content
Loading...

European Medicines Association (EMA) statement on Obeticholic acid for the treatment of primary biliary cholangitis (PBC) European Association for the Study of the Liver (EASL) perspective

  • Chiara Hartmann
  • news

The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market authorisation for Obeticholic acid in the European Union…

Read more

Launching the EASL Guidelines App!

  • Adonia DHANJAL
  • news

Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver, this app is meticulously designed to support healthcare…

Read more

LIVERSCREEN: A breakthrough in fighting liver disease

Liver diseases pose a significant global health challenge, with conditions like liver fibrosis often remaining undetected until they reach advanced stages, leading to severe consequences such as cirrhosis and liver cancer. In response to this pressing issue, the LIVERSCREEN project…

Read more

Tribute to Dr. Stephen Harrison (1969-2024)

The liver community mourns the loss of Dr. Stephen Harrison, a visionary in MASLD clinics and clinical research, whose contributions have shaped the current state of the field. Dr. Stephen Harrison was an early clinical researcher who dedicated his career…

Read more
Back To Top